Olumiant · DIN 02544768 · 4 mg · tablet
Limited Use, Reason for Use code 734 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 734 required
Write on scriptReason for Use code 734 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 734
Reason for Use code 734
Initiation criteria:
For the treatment of adult patients with severe alopecia areata (AA) who meet the following criteria:
1. Have a Severity of Alopecia Tool (SALT) score of 50 or above, and
2. Have experienced the current episode of AA for more than 6 months but less than 8 years.
The maximum duration of initial authorization is 36 weeks.
Renewal criteria:
For continuation of reimbursement, the patient must demonstrate beneficial clinical effect, defined as achieving a SALT score of 20 or less at 36 weeks after treatment initiation. Maintenance of a SALT score of 20 or less every 12 months thereafter is required for reimbursement renewal.
Dosing and prescribing:
The recommended dose is 2mg once daily. The maximum funded dose is 4mg once daily.
Baricitinib should be prescribed by a dermatologist with expertise managing patients with severe AA.
Baricitinib should not be used in combination with other JAK inhibitors, biologic immunomodulators, or systemic immunosuppressants.
Coverage limit:
LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Olumiant · DIN 02544768
Manufacturer: Eli Lilly Canada Inc.; listing date 2025-12-30
Health Canada: Marketed since 2024-04-09 · brand OLUMIANT · ATC L04AF02 BARICITINIB · form Tablet · route Oral · ingredients BARICITINIB 4 MG · company Eli lilly canada inc · schedule Prescription
Olumiant: Formulary list price $59.44 per unit (the source does not state the unit; exact figure $59.4367). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02544768)
Source record
DIN 02544768: Olumiant
Raw flags: sec12=Y, sec3=Y
Item: 924400021; group id 1049; item number 2405; lccId 00422; manufacturer id LIL
Source form: Tab; strength: 4mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $59.4367; ministry $59.4367
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02544768
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103336
Shortage status: not checked (no credentials)